GLT1D1 and cancer: Thus, it acts as a negative immune response regulator, leading to immune escapement of neoplastic cells.180,181 Immune checkpoint inhibitor drugs, anti-PD-1 or anti-PD-L1 antibodies, have been developed and found to be efficacious in treating a variety of human cancers.182 Glycosyltransferase 1 domain-containing 1 (GLT1D1) was found to be highly up-regulated in early relapsed DLBCL.